A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic Effect of MK-5160 in Subjects With Type 1 and Type 2 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2018
At a glance
- Drugs MK 5160 (Primary) ; Glucose; Insulin glargine
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Merck Sharp & Dohme
- 28 Feb 2018 Status changed from active, no longer recruiting to completed.
- 05 Feb 2018 Planned end date changed from 22 Jan 2018 to 5 Feb 2018.
- 05 Feb 2018 Planned primary completion date changed from 22 Jan 2018 to 5 Feb 2018.